Total Live Articles: 471

Gout

NICE guideline [NG219] Gout: diagnosis and management. Published: Jun 2022.

NICE CKS Gout. Last revised: Jun 2023.

Gout

Gout is a type of crystal arthropathy caused by the deposition of monosodium urate crystals within joints, resulting in episodes of acute inflammatory arthritis.

Causes and Risk Factors

Gout is characterised by the deposition of monosodium urate (MSU) crystals within the joint, which then triggers an inflammatory immune response

  • Urate is a metabolite of purines (an essential component of DNA/RNA material)

Hyperuricaemia (high serum urate level) is the most important predisposing factor.

Causes and risk factors by mechanism:

Causes of impaired renal excretion of urate (more common mechanism)
  • CKD
  • Other comorbidities (e.g. hypertension, diabetes, hyperlipidaemia, obesity)
  • Family history
  • Certain medications
    • Thiazide and loop diuretics
    • Aspirin
    • Pyrazinamide and ethambutol (TB drugs)
Causes of increased production of urate
  • Purine-rich diet (e.g. red meat, organs, seafood)
  • Lymphoproliferative / myeloproliferative disorders
  • Genetic metabolic disorders (e.g. Lesch-Nyhan syndrome, glycogen storage diseases)
  • Tumour lysis syndrome
  • Haemolysis
Mixed mechanisms (reduces renal excretion and increases urate production)
  • Excessive alcohol intake
  • Fructose-rich drinks / food
Demographic risk factors
  • Advanced age
  • Post-menopausal women
  •  Males

Importantly, gout may occur even when plasma urate levels are normal, while ~95% of individuals with hyperuricaemia never develop gout.

Clinical Features

Individuals with gout can be asymptomatic:

  • Asymptomatic hyperuricaemia, or
  • Intercritical gout (symptom-free period between acute gout flares while monosodium urate crystals remain in the joint tissue)
Acute gout Rapid onset of severe joint pain

  • Often develops overnight (click to see rationale)
  • The pain develops over a few hours and reaches maximum intensity within 24 hours
  • Pain is often exquisitely severe, and the affected joint may be so tender that the patient cannot tolerate even a bedsheet touching it

The affected joint is red, swollen, hot, extremely tender, and markedly reduced ROM

Acute gout typically causes a monoarticular arthritis. Affected joints include:

  • 1st MTP joint – most common (gout affecting this joint is historically called Podagra)
  • Knee
  • Ankles
  • Toes or fingers

Mild systemic upset (e.g. fever, malaise) is possible

Chronic gout Chronic gout usually develops after recurrent or inadequately treated acute gout flares and may present with:

  • More frequent flares with shorter symptom-free intervals
  • Progression from monoarthritis to oligoarticular or polyarticular disease
  • Chronic gouty arthritis – persistent joint pain, stiffness and swelling between acute attacks
  • Joint deformity
  • Tophi
    • Firm, painless subcutaneous nodules caused by the accumulation of monosodium urate crystals surrounded by chronic inflammation
    • Overlying skin is usually normal but may become thin, shiny or stretched if the tophus enlarges
    • The classic appearance of a white, chalky-like discharge occurs when the overlying skin ulcerates or if the tophus ruptures
    • Common sites include the helix of the ear, fingers, toes, elbows, olecranon bursae and Achilles tendon

Chronic tophaceous gout: advanced form of gout characterised by presence of tophi + chronic joint damage

Based on clinical history and examination alone, acute gout can be difficult to distinguish from septic arthritis, as both may present with an acutely painful, red, hot and swollen joint.

The presence or absence of systemic features, such as fever, is NOT reliable to differentiate between them.

Complications

Apart from development of chronic gout (see above), other complications include:

  • Permanent joint damage, deformity and functional impairment
  • ↑ Risk of urolithiasis (esp. uric acid renal stones)
  • Hyperuricaemia is also associated with an increased risk of
    • Cardiovascular disease and cardiovascular mortality
    • CKD

Investigation and Diagnosis

1st line test: serum urate level (interpreted within the clinical context)

  • ≥360 μmol/L or 6 mg/dL confirms the diagnosis of gout
  • If serum urate level is below the cut-off and gout is still suspected  → repeat the test at least 2 weeks after the flare has settled (as serum urate levels can sometimes drop during an active flare)

Key points in interpreting serum urate levels:

  • A typical clinical presentation PLUS elevated serum urate level strongly supports the diagnosis of gout
  • An elevated serum urate level alone is not diagnostic of gout, as many patients with hyperuricaemia never develop gout
  • A normal serum urate level does not exclude gout

2nd line (if diagnosis remains uncertain after testing serum urate level):

  • Joint aspiration for synovial fluid analysis and microscopy

3rd line (if joint aspiration cannot be performed and diagnosis remains uncertain):

  • Consider imaging of the affected joint(s) with ultrasound (more sensitive than X-ray) / X-ray / dual-energy CT 

NICE recommends measuring serum urate level as the first test in anyone with a typical acute monoarthritis in keeping with gout, due to its non-invasive property, high availability, and low cost

  • The NICE committee noted that joint aspiration and synovial fluid analysis remain the ‘gold standard’ test to diagnose gout when the diagnosis remains uncertain

Clinical pearl: A serum urate level alone cannot diagnose or exclude gout. Because acute gout and septic arthritis may present similarly, joint aspiration is often performed together with serum urate measurement when septic arthritis is a possibility

Synovial Fluid Analysis

Parameter Finding in Gout
Appearance Cloudy, yellow
Viscosity Reduced
WBC count and differential 2,000 – 50,000 cells/µL with polymorph (neutrophil) predominance
Crystals Needle-shaped monosodium urate crystals with strong negative birefringence
Gram stain / culture -ve
Glucose Normal

Synovial fluid microscopy in crystal arthropathy

  • Gout (monosodium urate crystals): needle-shaped crystals with negative birefringence
  • Pseudogout (calcium pyrophosphate crystals): rhomboid-shaped with positive birefringence (pseudogout = positive)

Management

Acute Gout Attack

Conservative management:

  • Apply ice to the affected joint
  • Continue any pre-existing urate-lowering drugs (allopurinol or febuxostat) – if the patient is taking these medications and has an acute gout attack

Pharmacological management:

  • 1st line: NSAID + PPI (e.g naproxen, ibuprofen, but NOT aspirin) OR colchicine OR oral corticosteroid (short-course)
    • NICE committee acknowledges that in practice NSAIDs or colchicine is typically 1st line, preferred over corticosteroids
  • 2nd line: intra-articular / intramuscular corticosteroid injection
  • 3rd line: IL-1 inhibitor (e.g. anakinra, canakinumab) (to be prescribed by specialist)

Some reasons to avoid NSAIDs:

  • History of peptic ulcer disease or GI bleed
    • Esp. if there is increased risk of GI bleed e.g. concurrent use of anticoagulants
  • Chronic kidney disease
  • Cardiovascular comorbidity (esp. congestive heart failure and cardiovascular disease)

Some reasons to avoid colchicine:

  • Severe renal impairment (in these patients both NSAIDs and colchicine would not be appropriate → oral corticosteroids are more appropriate)
  • Intolerance to diarrhoea (common and main side effect of colchicine)
  • Severe hepatic impairment
  • Concurrent use of strong CYP3A4 or P-glycoprotein inhibitors (e.g. macrolides, ketoconazole, ciclosporin) – increases colchicine concentration and risk of toxicity

Long Term Management

Diet and Lifestyle

  • Advise patients to follow a healthy, balanced diet
    • At least 5 portions of fruit and vegetables per day
    • Low-sugar and low-fat products
    • Eat less food that is high in sugar and fat
    • Eat more wholegrain starchy food rather than white refined food
    • Use healthy cooking methods (e.g. grilling, dry roasting, steaming)
  • Advise that excess body weight, obesity, and excessive alcohol consumption may exacerbate gout flares and symptoms

Specific diet advice for gout:

Food to avoid (high purine food)
  • Offal (organ meat) – e.g. liver and kidney
  • Game meat – e.g. rabbit, venison, pheasant
  • Seafood – e.g. prawns, mussels, clams
  • Oily fish – e.g. anchovies, mackerel, herring, sardines
Food that can be eaten freely (low purine food)
  • Fruits and vegetables
  • Dairy – e.g. milk, yoghurt, cheese
  • Dairy-free alternatives – e.g. soya and other plant-based products
  • Eggs
  • Bread and cereals not containing bran
  • Pasta, rice, and noodles
  • Nuts
  • Beans, lentils and pulses
Beverages
  • Avoid dehydration (drink plenty of water)
  • Avoid sugar-sweetened drinks
  • All alcohol can make gout worse (esp. beer, ale, fortified wine, port)
  • Coffee is beneficial

Urate-Lowering Therapy (ULT)

Indications Discuss the option of ULT to ALL patients who experienced a first or subsequent gout flare

ULT should be offered if ANY of the following are present:

  • Multiple or troublesome flares
  • CKD stages 3 to 5
  • Diuretic therapy
  • Tophi
  • Chronic gouty arthritis
Initiating ULT ULT should be started at least 2-4 weeks after a gout flare has settled

Bridging preventive therapy should be offered to cover the period while ULT is being started and the dose is being titrated until below the target

  • 1st line: colchicine
  • Alternative: low-dose NSAID or low-dose oral corticosteroid

If ULT is started during the acute gout flare, reducing serum urate levels can destabilise monosodium urate crystals in joint tissues, making the flare worse or prolonged.

Exception: if the patient has very frequent flares with no 2-4 weeks of flare-free period → start the ULT during an active flare (along with bridging preventive therapy)

Choice of ULT 1st line: allopurinol or febuxostat (both are xanthine oxidase inhibitors)

In patients with major CVD (e.g. previous MI, stroke, unstable angina):

  • Febuxostat should be avoided
  • Offer allopurinol instead
Target ULT should be offered with a treat-to-target strategy:

  • Start with a low dose
  • Use monthly serum urate level to guide dose adjustment
  • Target serum urate level:
    • <360 μmol/L or 6 mg/dL for most patients
    • Consider a tighter target of <300 μmol/L or 5 mg/dL for those with tophi / chronic gouty arthritis / who continue to have frequent flares despite being below the initial target

Duration of treatment: ULT is typically lifelong (continued even after target serum urate level is reached)

Do NOT offer ULT to those with high serum urate levels for gout primary prophylaxis (i.e. to prevent a first gout attack in those who never had gout but just a high serum urate level).

Rationale: most patients with hyperuricaemia do NOT actually develop gout.

References

Share Your Feedback Below

Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Stay Updated withGuideline Genius

Sign up to be notified when our newsletter launches, covering major guideline updates, article updates, and future UKMLA resources.